It's BMS vs. Celgene investors once more after US appeals court revives lawsuit
A U.S. appeals court revived a lawsuit by Celgene shareholders against Bristol Myers Squibb over Breyanzi’s late FDA approval and a CVR tied to $9 per share. The court said a 2024 dismissal was wrong on trustee jurisdiction, citing acceptance of UMB Bank as trustee. The dispute stems from BMS’s 2019 Celgene $74B deal and a potential $6.4B payout.
How this was made
The 30-second read
Why it matters
A 3-0 appeals court decision overturned a 2024 dismissal, ruling the trustee (UMB Bank) had subject matter jurisdiction despite alleged defects in trustee appointment, and emphasizing BMS accepted the trustee’s status.
Market read
Revived litigation keeps CVR-related damages risk alive for BMY, potentially affecting how investors discount pharma M&A contingent-payment structures.
What to watch
The article notes uncertainty about how the appeals ruling affects a separate breach-of-contract case, so the incremental near-term damages path may be less direct than headline suggests.
Background
The dispute stems from BMS’s 2019 acquisition of Celgene for $74B, including a CVR paying $9 per share if three drugs, including Breyanzi, received FDA approval by end-2020.
Ticker impact
Bristol Myers Squibb is the defendant in the revived Celgene shareholder lawsuit over alleged slow-walking Breyanzi approval to avoid CVR payout.
Near-term risk premium likely modestly negative for BMY until litigation posture or damages estimates clarify.
The decision reinstates claims and keeps contingent-value exposure in focus, but the article does not quantify incremental damages beyond the previously cited CVR amount.
Market effects
Highlights CVR and approval-timing litigation risk for pharma M&A deals with milestone-based contingent payments.
Primarily US legal/regulatory process risk, with potential spillover to other pharma acquirers using CVRs.
US court precedent may influence how investors price contingent-payment structures in cross-border pharma transactions.
Counterpoint
BMY may argue the underlying Breyanzi approval delay was driven by regulatory and manufacturing issues, not intentional slow-walking, limiting downside from the revived case.
Key entities
- companyBristol Myers Squibb
Defendant in the revived shareholder lawsuit alleging slow-walking Breyanzi approval to avoid CVR payout.
- companyCelgene
Acquired in 2019 by BMS; its shareholders are plaintiffs via a CVR-related lawsuit.
- financial_institutionUMB Bank
Trustee whose appointment defects were cited in the prior dismissal, now rejected as a jurisdictional bar.
- drugBreyanzi
Blood cancer drug at the center of the CVR timing dispute; FDA approval came after the CVR deadline.
- companyLonza
Third-party manufacturer whose facility inspection failure is cited as a reason for Breyanzi approval delay.
